Alexandria Forbes, Ph.D.President and CEO
Dr. Alexandria Forbes is President and CEO of MeiraGTx. Previously, Dr. Forbes served as Senior Vice President of Strategic Operations and Chief Commercial Officer at Kadmon Corporation. Prior to joining Kadmon in 2013, Dr. Forbes spent 13 years as a healthcare investor at Sivik/Argus Partners and Meadowvale Asset Management. Dr. Forbes was a portfolio manager responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and at Sivik/Argus Partners she managed the Global Life Science Fund, a long-biased fund focused on biotechnology. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University. Dr. Forbes received her Ph.D. from Oxford University and her M.A. from Cambridge University.
Robin Ali, Ph.D.Chief Scientific Officer
Professor Robin Ali is Chief Scientific Officer of MeiraGTx. He is also Professor of Human Molecular Genetics at UCL Institute of Ophthalmology. Additionally, he is the Theme Leader for Gene Therapy at NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital and a Visiting Professor at The Kellogg Eye Center, University of Michigan.
Prof. Ali established the world’s first clinical trial of gene therapy for retinopathy. In 2007, he was elected to the UK Academy of Medical Sciences and in 2009 appointed Senior Investigator of The UK National Institute of Health Research. He is President-Elect of the European Society of Gene and Cell Therapy and has served on the advisory boards of a number of funding bodies including the UK Medical Research Council (Neurosciences and Mental Health Board and the Regenerative Medicine Research Committee), Research to Prevent Blindness USA and Fighting Blindness Ireland, as well as the advisory boards of pharmaceutical and biotech companies, including Alcon/Novartis.
Prof. Ali obtained his BSc (1988) and PhD in Genetics (1993) at University College London, carried out his postdoctoral training at the MRC National Institute for Medical Research and the UCL Institute of Ophthalmology and established his laboratory at the UCL Institute of Ophthalmology in 1999.
Stuart Naylor, Ph.D.Chief Development Officer
Dr. Stuart Naylor is Chief Development Officer of MeiraGTx. From 2008 to 2013, Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, one of the world’s first gene therapy companies, where he pioneered the development of the company’s ocular products. Prior to joining Oxford BioMedica in 1997, Dr. Naylor’s career focused on translational cancer research, initially at the Imperial Cancer Research Fund’s Central Laboratories in London and subsequently at the Institute of Cancer Research working in the areas of cytokine and tumor biology. Dr. Naylor has a first degree in microbiology and virology, a Master’s degree in Immunology, and earned a Ph.D. from the Imperial Cancer Research Fund laboratory studying ovarian cancer and cytokine biology.
Richard GirouxChief Operating Officer
Richard Giroux is Chief Operating Officer of MeiraGTx and brings 20 years of leadership and experience in capital markets in finance and healthcare to his position. Prior to joining MeiraGTx, Rich was at Sarissa Capital Management LP, an activist healthcare hedge fund. In 2010, Mr. Giroux helped launch and operate Meadowvale Partners, a multi-strategy hedge fund, where he was a founding partner and healthcare portfolio manager. Prior to Meadowvale, he was a partner at Sivik Global Healthcare (formerly Argus Partners), a long/short global equity healthcare fund. From 1996 to 2001, he worked in the equity derivative divisions of Goldman Sachs and Citigroup (formerly Salomon Smith Barney) where he structured, marketed and traded derivative and cash products for domestic and international hedge funds and asset allocators. Mr. Giroux received his BA in Economics from Yale University in 1995.